Open AccessA new strategy for the treatment of sorafenib-refractory metastatic renal cell carcinoma in China: combination with intermittent chemotherapy
Author(s) -
Zicheng Xu,
Xiao Li,
Feng Qi,
Xin Hu,
Yuxiao Zheng,
Hongzhou Cai,
Ting Xu,
Bin Yu,
Qing Zou
Publication year - 2019
Publication title -
translational andrology and urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.721
H-Index - 27
eISSN - 2223-4691
pISSN - 2223-4683
DOI - 10.21037/tau.2019.06.25
Subject(s) - medicine , sorafenib , gemcitabine , refractory (planetary science) , renal cell carcinoma , chemotherapy , progressive disease , gastroenterology , oncology , surgery , urology , hepatocellular carcinoma , physics , astrobiology
This study assesses the clinical safety and efficacy of Gemcitabine and S-1 combination chemotherapy in sorafenib-refractory metastatic renal cell carcinoma (RCC) patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom